Results 171 to 180 of about 28,926,907 (345)

Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis

, 2020
Yutao Wang, Kexin Yan, Jiaxing Lin, Jianfeng Wang, Zhenhua Zheng, Xinxin Li, Zhixiong Hua, Yue-Peng Bu, Jianxiu Shi, Siqing Sun, Xuejie Li, Yang Liu, Jianbin Bi   +12 more
openalex   +2 more sources

28P 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms [PDF]

, 2023
F. Stenner-Liewen, Matt D. Galsky, Dean F. Bajorin, J.A. Witjes, Jürgen E. Gschwend, Yoshihiko Tomita, F. Nasroulah, Margarita Askelson, Begoña P. Valderrama, Marc‐Oliver Grimm, Leonard J. Appleman, Gwénaëlle Gravis, Andrea Necchi, D. Ye, J.M. David   +14 more
openalex   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study

The World Journal of Men's Health
Purpose: Androgen signaling is associated with various secondary cancer, which could be promising for potential treatment using androgen deprivation therapy (ADT). This study investigated whether ADT use was associated with secondary cancers other than
Jae Heon Kim, Gi Hwan Bae, Jaehun Jung, Tae Il Noh   +3 more
doaj   +1 more source

Landmark mediation survival analysis using longitudinal surrogate

, 2023
Jie Zhou, Xun Jiang, H. Amy Xia, Brian P. Hobbs, Peng Wei   +4 more
openalex   +1 more source

Investigating the post-complaint period by means of survival analysis [PDF]

, 2005
Larivière, Bart, Van den Poel, Dirk
core   +2 more sources

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

In Flight Cardiac Arrest (IFCA) Survival: A Concept Analysis

, 2022
Manjushambika Rajagopal
openalex   +2 more sources

Characterizing epithelial‐mesenchymal transition‐linked heterogeneity in breast cancer circulating tumor cells at a single‐cell level

Molecular Oncology, EarlyView.
In over 50% of non‐metastatic breast cancer patients, circulating tumor cells (CTCs) along the whole epithelial‐mesenchymal transition spectrum are detected. Total CTC number and individual phenotypes relate to aggressive disease characteristics, including lymph node involvement and higher tumor proliferation. At the single‐cell level, mesenchymal CTCs
Justyna Topa, Julia Richert, Tomasz Stokowy, Alicja Staśczak, Mariusz Szajewski, Maciej Ciesielski, Petra M. Grešner, Bartłomiej Tomasik, Łukasz Arcimowicz, Agnieszka Stankiewicz, Grażyna Suchodolska, Elżbieta Senkus, Wiesław Kruszewski, Anna J. Żaczek, Aleksandra Markiewicz   +14 more
wiley   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source